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In 2017, more than 1.1 million children were living with type 1 diabetes mellitus (T1DM) glob-
ally. The goal in paediatric diabetes therapy is reaching optimal glycaemic control as early
as possible in order to avoid complications and early mortality without compromising the
quality of life (QoL) of children. Several different insulin regimens are available for T1DM
patients to reach this goal.
Aims
This review set out to analyse whether continuous subcutaneous insulin infusion (CSII) regi-
mens are superior to multiple daily injection (MDI) therapy in T1DM youth regarding QoL.
Additionally, it assessed glycaemic control and adverse events as secondary outcomes and
discussed potential future public health implications and justifications for using CSII as a
first-line therapy in diabetic youth.
Methods
A systematic review and random effects meta-analysis was performed on studies investigat-
ing the association between QoL and diabetes treatment regimen. Differences in adverse
event rates between groups were analysed using a Mann-Whitney U test. Lastly, differences
in glycaemic control were assessed using a random effects meta-analysis.
Results
QoL and glycaemic control was significantly better in CSII subjects at baseline and follow-
up. No significant differences in adverse events were found between study groups. No sig-
nificant changes over time could be shown for either QoL or glycaemic control.
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Conclusion
CSII proved to provide similar or slightly better outcomes in all analysed fields. This is con-
sistent with previous research. However, to make credible recommendations, better-
designed studies are needed to investigate the impact of CSII in children.
Introduction
Diabetes mellitus (DM) is one of the top ten causes of global mortality, having killed 1.6 mil-
lion people in 2016 alone.[1–3] DM describes a cluster of metabolic diseases, rather than a sin-
gle illness, that are characterised by chronic hyperglycaemia.[4] The American Diabetes
Association (ADA) classifies DM into four general categories with the most common ones
being type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) following in sec-
ond place.[4, 5] It is estimated that more than 96,000 children under the age of fifteen are diag-
nosed with T1DM annually, whilst there are 1.1 million children and adolescents below 20
years living with T1DM globally.[6] There are considerable regional differences in the preva-
lence of T1DM with more than one quarter (28.4%) of paediatric patients living in Europe and
more than one fifth (21.5%) living in North America and the Caribbean.[6] The highest inci-
dence of T1DM can be seen in the United States (US), India and Brazil.[6] Complications in
T1DM are relatively frequent and can be divided into acute (e.g. diabetic ketoacidosis, infec-
tion) and chronic (macro- and microangiopathy). In addition to being a global health problem
due to its multiple short and long-term complications, diabetes and related conditions account
for an enormous economic burden throughout the world.[7] This burden is expected to con-
tinue growing with a projected expenditure of 776 billion US-Dollar by 2045 for adult patients
only.[6] T1DM’s physiopathology is primarily due to β-cell destruction and absolute insulin
deficiency.[4] Thus, the therapeutic goal for T1DM patients is defined as reaching optimal gly-
caemic control as early as possible to avoid acute and chronic complications without
compromising the quality of life (QoL) and wellbeing of children, their parents or caregivers.
[8] The only way to reach this goal for patients with T1DM is—additionally to behavioural
interventions—the uninterrupted supply of insulin.[6] Insulin regimens available for T1DM
patients can be divided into three groups: multiple daily injection basal-bolus insulin regimens
(MDI), mixed (biphasic) regimens and continuous subcutaneous insulin infusion regimens
(CSII, insulin pump). Despite MDI still being the first-line therapy in many regions around
the world[9–11] CSII is gaining popularity among paediatric patients.[12] This can be
explained to some extent by slightly better metabolic control and less acute complications
through CSII[12–14] but might also be influenced by other factors not yet fully understood.[8]
With CSII being much more expensive than MDI–treatment cost would increase by 50% if all
T1DM patients used CSII[15]–methodologically well-conducted studies are needed to prove
its superiority over MDI and to justify it as a first-line choice.
So far, reviews investigating insulin pump therapy showed mixed results regarding the
health-related quality of life (HRQOL) in paediatric diabetes patients.[13, 16, 17] According to
recent publications,[15, 18–20] there is still a lack of adequately powered studies to underpin
the advantages of CSII regarding QoL improvement for children diagnosed with DM and to
potentially balance the higher treatment cost attached to it.[8] Thus, insulin pumps are–forty
years after they were first introduced to the market–still not part of first-line recommendations
in most countries around the world. The aim of this systematic review and meta-analysis is to
analyse available evidence on whether CSII is superior to MDI therapy in T1DM youth
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regarding HRQOL. In addition, this work will assess glycaemic control and adverse events as
secondary outcomes, since a close relationship between HRQOL and glycaemic control has
been previously described. A thorough understanding of the links between both outcomes
could have important implications for the adoption of CSII in paediatric diabetes care.[18]
Finally, the paper will discuss the potential future public health significance and whether there
is justification for using CSII as a first-line therapy in children and adolescents.
Methods
T1DM is the most common type of diabetes in children.[6] Although T2DM is becoming
more common in children and adolescents in some regions around the world, sufficient and
reliable data on T2DM in childhood is sparse which makes an analysis of its global health
impact difficult. Whereas T1DM can only be treated by insulin injections, there are multiple
options for T2DM. Thus, this work will focus on paediatric patients with T1DM only. The def-
inition of childhood provided by the World Health Organization (WHO) was used to set an
age threshold for study inclusion criteria. According to the WHO, an adolescent is a person
“10 to 19 years inclusive” and a child “is a person 19 years or younger”.[21] Therefore, studies
including participants older than 19 years were excluded.
Eligibility criteria
Studies were selected for inclusion according to the criteria stated (Table 1). Eligibility criteria
were formulated before the primary literature search.
Literature search strategy
A systematic literature search was performed on 12 December 2018 using PubMed, Web of
Science and the Cochrane Library as primary data sources (Table 2 and Fig 1). Studies were
selected upon meeting the eligibility criteria stated in Table 1. Additionally, Google.com was
searched for grey literature and supplementary data sources. Also, reference lists of included
studies and past reviews were screened for more relevant articles. Two levels of screening by
two independent researchers (B. Rosner and A. Roman-Urrestarazu) were used on all cita-
tions. Our electronic search yielded 1,733 articles (Fig 1). We reviewed the titles and abstracts
and eliminated any articles that clearly fell outside our inclusion/exclusion criteria. If there
was any doubt, the article was retained for the next level of scrutiny. This process yielded 124
articles. Two authors examined each article’s title and abstract more closely and, if needed,
Table 1. Inclusion and exclusion criteria for study selection.
Inclusion criteria Exclusion criteria
1. Studies comparing quality of life between
CSII regimens and MDI
2. Studies solely focused on children and
adolescents (WHO definition) with T1DM
3. Primary data analysis
4. Full-text accessible at University of
Cambridge or University of Groningen
5. Language: English
6. Geographic region: Worldwide
1. Studies comparing quality of life between CSII regimens and
control groups other than MDI (e.g. healthy controls, other
pump regimens)
2. Studies solely referring to closed-loop systems or sensor-
augmented pump therapy
3. Studies focused on type 2 diabetes mellitus (T2DM)
specifically
4. Studies not primarily assessing quality of life
5. No restriction to children and/or adolescents (WHO
definition)
6. Full-text not accessible at University of Cambridge or
University of Groningen
7. Languages other than English
8. Review, meta-analysis
https://doi.org/10.1371/journal.pone.0217655.t001
A systematic review and meta-analysis of insulin infusion systems
PLOS ONE | https://doi.org/10.1371/journal.pone.0217655 June 25, 2019 3 / 21
examined the full text of each article and made independent judgments as to whether the arti-
cle met inclusion and exclusion criteria. Disagreements were resolved by face-to-face discus-
sion, leading to a consensus judgement. Fifteen articles met our inclusion and exclusion
criteria.
Quality assessment of included studies and literature bias analysis
The Effective Public Health Practice Project Tool (EPHPP) was used to assess and compare the
quality of included studies.[22, 23] The EPHPP allows for the evaluation of internal (study
design, confounding, blinding, withdrawals and dropouts, intervention integrity, analyses) as
well as external (data collection methods, selection bias) validity of studies.[24] The quality
assessment results are summarised in the S1 Table.
We used ratio measures of intervention effect (Odds ratios) and plotted on a logarithmic
scale to evaluate possible literature bias in Funnel Plots, using Egger test as well. The aim of
this was to ensure that effects of the same magnitude but opposite directions were equidistant
from 1. For outcomes measured on a continuous (numerical) scale (e.g. blood pressure,
depression score) intervention effects were measured as standardised mean differences. For
mean differences, the standard error was approximately proportional to the inverse of the
square root of the number of participants.
Table 2. Search terms included in database search.
Database Search Strategy
PubMed 1. quality of life OR QoL OR quality of life [MeSH]
AND
2. diabetes OR diabetes mellitus type 1 OR insulin-dependent diabetes OR diabetes mellitus, type 1
[MeSH]
AND
3. insulin OR continuous subcutaneous infusion OR continuous subcutaneous injection OR CSII
OR pump therapy OR insulin infusion systems [MeSH]
AND
4. children OR child� OR newborn OR infant� OR teenagers OR teenag� OR adolescent� OR child





1. quality of life OR QoL
AND
2. diabetes OR diabetes mellitus type 1 OR insulin-dependent diabetes
AND
3. insulin OR continuous subcutaneous infusion OR continuous subcutaneous injection OR CSII
OR pump therapy
AND
4. children OR child� OR newborn OR infant� OR teenagers OR teenag� OR adolescent�
Filters: English; all years; all fields
Cochrane 1. quality of life OR QoL OR quality of life [MeSH]
AND
2. diabetes OR diabetes mellitus type 1 OR insulin-dependent diabetes OR diabetes mellitus, type 1
[MeSH]
AND
3. insulin OR continuous subcutaneous infusion OR continuous subcutaneous injection OR CSII
OR pump therapy OR insulin infusion systems [MeSH]
AND
4. children OR child� OR newborn OR infant� OR teenagers OR teenag� OR adolescent� OR child
[MeSH] OR adolescent [MeSH] OR infant [MeSH] OR infant, newborn [MeSH]
No filters used.
https://doi.org/10.1371/journal.pone.0217655.t002
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Data collection and quantitative analysis
The data extracted from each study comprised lead author, sample characteristics, study set-
ting, study design, follow-up details, information on exposure and outcome measurements as
well as on confounders. Means were used as the main measures of association across studies. If
more than one effect size was reported for the same relationship, the maximally adjusted
model was chosen. A comparison between baseline and follow-up data was not always possible
due to differences in study design between papers. To analyse the association between
HRQOL and insulin treatment regimen standardised mean differences (SMD) were calculated
for each study (see below) at two time points (baseline and follow-up) using the reported mean
HRQOL scores for each group (CSII and MDI). This approach is endorsed by the Cochrane
Collaboration when studies included in a meta-analysis assess the same outcome but measure
it in a variety of ways (e.g. use different assessment tools).[25] SMD were entered into the ran-
dom effects meta-analysis as primary effect measures.
SMD :
Difference in mean outcome between groups
Standard deviation of outcome among participants
Due to heterogeneity in used QoL assessment tools a Mann-Whitney U test was carried out
to look for potential associations between adverse event rates per patient year and the assigned
Fig 1. Literature search strategy.
https://doi.org/10.1371/journal.pone.0217655.g001
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treatment groups, the hypothesis being that lower incidence of adverse events would create a
higher QoL.[26, 27] Additionally, HbA1c (glycated haemoglobin in %) was assessed as a sec-
ondary outcome to evaluate the effectiveness of the different treatment regimens (glycaemic
control) and to account for it as a potential confounder throughout studies. Mean differences
(MD) between treatment groups at baseline and follow-up were retrieved from each paper and
entered into a random effects meta-analysis to approximate an overall pooled effect size for
each point in time. If HbA1c measures were not reported in per cent of total haemoglobin but
in mmol/mol the following formula was used for conversion:[28]
HbA1c ð%Þ ¼ ½0:09148 �HbA1c ðmmol=molÞ� þ 2:152
Random effects models were chosen for all meta-analyses because of anticipated between-
study variance. Heterogeneity was judged by using the Cochran Q test and the I2 statistic
which gives the percentage of between-study variation attributable to heterogeneity.[29] If not
stated otherwise the significance level was set to 0.05. All statistical analyses were performed
using STATA IC Version 15.1.[30]
Results
Fifteen eligible studies could be identified and were included in the analysis of this paper with
an agreement percentage between raters of 89.5% and Cohen’s Kappa: 0.604 (Table 3). No
additional data was included through screening of references and grey literature. The overall
quality of studies was poor (S1 Table). Eligible papers were published between 2003 and 2018,
sample sizes ranged from 16 to 700 and all studies included male and female patients in their
analyses. Study centres were based in the US[31–34], Germany[8, 35], Denmark[36, 37], Italy
[38], the Netherlands[39], Hungary[40], England and Wales[15], and Israel[41–43] (with one
of the Israeli studies additionally including patients from a study site in Slovenia[41]).
Research methodology varied substantially, particularly because of different study designs
used. Six studies were randomised controlled trials (RCT)[8, 15, 33, 39, 42, 43] (of which two
applied a crossover design[42, 43]), another six were cross-sectional studies (CSS)[31, 32, 34,
36, 38, 40] and one each were a clinical trial (CT)[37], a crossover CT[41] and a prospective
observational study[35]. The age of study participants ranged from 0.6 to 19 years (Table 3).
Three of the studies[8, 15, 35] stated results for different age groups with Mueller-Godeffroy
et al.[8, 35] and Blair et al.[15] reporting for patient cohorts younger than 8 years, 8–11 years,
12–16 years and cohorts younger than 5 years, 5–11 years, 12–15 years respectively. Inclusion
criteria typically consisted of all patients being diagnosed with T1DM, being currently treated
with MDI (RCT) or being either treated with CSII or MDI (CSS) before the study. Only one
paper included newly diagnosed T1DM patients with no prior treatment.[15] Given consent
by patients and their parents as well as the absence of major comorbidities were additional eli-
gibility criteria. All studies reported HbA1c and QoL as outcome measures, nine studies[15,
33, 35, 37–39, 41–43] stated the number of occurred adverse events within each study group
(Table 4). Other reported secondary outcomes—which are not the focus of this review—were
cardiorespiratory fitness, parenting stress, treatment satisfaction, insulin dose, BMI, hypogly-
caemia fear and cost-effectiveness.
Quality of life
All included studies reported QoL measures using eight different assessment tools (Table 4).
Both studies by Mueller-Godeffroy et al. used the KINDL-DM[8, 35], the Pediatric Quality of
Life Inventory (PedsQL)[15, 36, 39, 40] and the Diabetes Quality of Life for Youth Question-
naire (DQOL-Y)[32, 34, 42, 43] were used in four papers respectively. Cherubini et al. assessed
A systematic review and meta-analysis of insulin infusion systems
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Table 3. Study characteristics for selected studies.























211 6–16 Germany RCT�� 6 H, Q KINDL-DM Baseline, age,
































2014 2009 700 8–17 Denmark CSS N/A H, Q PedsQL Gender, age,
diabetes duration
and HbA1c








































117 4–16 Germany Prospective
observational
study




















Wilson [33] Diabetes Care 2005 2001–
2003
19 1–6 USA RCT 12 G, H, K, Q DQOL for toddlers Not given











A systematic review and meta-analysis of insulin infusion systems
PLOS ONE | https://doi.org/10.1371/journal.pone.0217655 June 25, 2019 7 / 21
QoL using the Insulin Delivery System Rating Questionnaire (IDSRQ)[38], Rendell et al. used
the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF)[31] and
Johannesen et al. did not state the name of the applied questionnaire.[37] Two studies used
modified versions of the Diabetes Quality of Life Questionnaire (DQOL).[33, 41] Three studies
reported both QoL at baseline and at follow-up.[8, 33, 39] Six studies reported significantly
higher QoL in the CSII group compared to MDI subjects,[8, 35, 38, 40, 41, 43] three studies
reported that QoL in the CSII cohort was higher but the difference did not reach significance
level.[15, 31, 36] Six papers could not find a difference between QoL in MDI and CSII users.
[32–34, 37, 39, 42] Due to large heterogeneity in QoL assessment tools and differences in
reporting of QoL (e.g. missing CIs, reporting of medians instead of means), only SMD for
baseline data from two studies[8, 39] (one study reporting separately for two age groups)[8]
and SMD for follow-up data from five studies[8, 32, 36, 39, 40] (one study reporting separately
for two age groups again)[8] could be pooled for an overall effect estimate using a random
effects meta-analysis (Fig 2 and Fig 3).
The effect estimates at baseline do not suggest significantly relevant heterogeneity (I2 =
0.0%). The pooled estimates show a significant overall SMD in QoL favouring the CSII group
(Overall SMD -0.3 (-0.02, -0.57); p = 0.035).
At follow-up, the entered effect estimates suggest substantial heterogeneity (I2 = 61.1%)
between studies. The pooled estimates suggest significantly better QoL in the CSII group
(Overall SMD -0.37 (-0.14, -0.60); p = 0.002). The pooled estimated SMD in QoL between
study groups was more prominent at follow-up, but still only showing a small difference.
Changes between baseline and follow-up over time did not reach significance level. CSII
groups reported significantly better QoL at both measurements.
Adverse events
Nine studies included adverse events in their results (Table 4).[15, 33, 35, 37–39, 41–43] Eight
studies reported numbers for both severe hypoglycaemia and ketoacidosis with solely Mueller-
Godeffroy et al.[35] reporting numbers for hypoglycaemia only. Eight studies did not suggest
any significant differences in adverse events between treatment groups.[15, 33, 35, 37, 38, 41–
43] Nuboer et al. did show a threefold decrease of hypoglycaemia incidence in CSII subjects
Table 3. (Continued)
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https://doi.org/10.1371/journal.pone.0217655.t003
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Table 4. Quality of life, HbA1c and adverse events data from all included studies.
HbA1c (%)� Quality of life�� Adverse events
(per person year)���
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Table 4. (Continued)
HbA1c (%)� Quality of life�� Adverse events
(per person year)���
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but did not state significance of the result. Also, no differences in ketoacidosis incidence were
found. The performed Mann-Whitney U test did neither show any significant difference in
severe hypoglycaemia rates (p = 0.2888) nor in ketoacidosis rates (p = 0.1052) between treat-
ment groups (Table 5 & Table 6). Results suggest that incidence rates per patient year for
severe hypoglycaemia were slightly higher with MDI. However, incidence rates for ketoacido-
sis proved to be higher with CSII treatment.
HbA1c
HbA1c measures were reported by all studies (Table 4). Seven studies included baseline data[8,
15, 33, 37, 39, 42, 43] and one study did not report numbers for HbA1c at follow-up.[38] Five
papers found significantly lower HbA1c levels in CSII subjects.[34–36, 39, 41] However, one
study only reported significant results for one age group.[35] Ten studies did not find signifi-
cant differences between treatment groups.[8, 15, 31–33, 37, 38, 40, 42, 43] All but two studies
[15, 38] reported better HbA1c measures for CSII. Cherubini et al. did not state any numbers
and Blair et al. did report better HbA1c outcomes for one of the three examined age groups
only. Due to differences in reporting of HbA1c (e.g. missing CIs, reporting of medians instead
of means, etc.), only MD for baseline data from six studies[8, 15, 37, 39, 42, 43] (one study
reporting separately for three age groups)[8] and MD for follow-up data from eleven studies[8,
15, 31, 32, 34, 35, 39–43] (three studies reporting separately for three age groups again)[8, 15,
35] could be pooled for an overall effect estimate using a random effects meta-analysis (Fig 4
and Fig 5).
The effect estimates at baseline do not suggest significantly relevant heterogeneity (I2 =
0.0%). The pooled estimates show a significant overall mean difference in HbA1c favouring
CSII (Overall MD -0.23 (-0.42, -0.04); p = 0.019). The calculated effect estimates at follow-up
suggest substantial heterogeneity (I2 = 57.3%) between studies. Again, pooled estimates show a
Table 4. (Continued)
HbA1c (%)� Quality of life�� Adverse events
(per person year)���
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https://doi.org/10.1371/journal.pone.0217655.t004
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significant mean difference between groups favouring CSII (Overall MD -0.26 (-0.44, -0.08);
p = 0.005).
The estimated mean difference in HbA1c between study groups was bigger at follow-up.
CSII groups reported lower HbA1c at both measurements with an even more significant dif-
ference between study groups at follow-up. However, changes over time did not reach signifi-
cance level.
The results of the Funnel Plots and Egger test to evaluate publication bias in HbA1C at
baseline and follow and QoL, showed only an asymmetrical appearance in the HbA1C at base-
line (please see supplementary material for all analyses). Assuming that studies with high pre-
cision should be plotted near the average, and those with low precision should be spread
evenly on both sides of the average, one can clearly see that in the case of HbA1C at baseline
the distribution of studies tends to be concentrated towards a value of 0 which is suggestive of
certain publication bias.
Discussion
The current meta-analysis could show significant differences in QoL between paediatric CSII
and MDI users at follow-up. However, QoL was better in CSII subjects at baseline, too, which
is a bias potentially mitigating the validity of the performed analysis. No significant change in
Fig 2. Pooled quality of life results (SMD) at baseline.
https://doi.org/10.1371/journal.pone.0217655.g002
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QoL over time could be observed. The evidence suggested no significant differences in adverse
event incidence between treatment groups. Severe hypoglycaemia incidence was higher in
MDI subjects whereas ketoacidosis incidence was shown to be higher in CSII subjects. A sig-
nificant difference in glycaemic control could be shown between treatment groups both, at
baseline and follow-up, with CSII yielding lower HbA1c values at both points in time respec-
tively. Despite the difference being more prominent at follow-up, no significant change could
be shown over time.
Fig 3. Pooled quality of life results (SMD) at follow-up.
https://doi.org/10.1371/journal.pone.0217655.g003
Table 5. Mann-Whitney U test for comparison of hypoglycaemia rates between treatment groups.
Treatment group Observations Rank sum Expected
CSII 9 73.5 85.5
MDI 9 97.5 85.5
Combined 18 171 171
H0: Hypoglycaemia CSII = Hypoglycaemia MDI
z = -1.061
Prob > |z| = 0.2888
https://doi.org/10.1371/journal.pone.0217655.t005
A systematic review and meta-analysis of insulin infusion systems
PLOS ONE | https://doi.org/10.1371/journal.pone.0217655 June 25, 2019 13 / 21
Several limitations of the included literature have to be considered when interpreting the
results of this work. Specific methodological issues are described in Table 7. The described het-
erogeneity is in part reflected in statistical results of the meta-analysis with both the pooled fol-
low-up estimates of QoL and HbA1c analyses showing substantial and considerable
heterogeneity respectively. In addition to limitations of the included literature there are also
relevant limitations to this review itself (Table 8). Due to the small number of studies included
Table 6. Mann-Whitney U test for comparison of ketoacidosis rates between treatment groups.
Treatment group Observations Rank sum Expected
CSII 8 82 68
MDI 8 54 68
Combined 16 136 136
H0: Ketoacidosis CSII = Ketoacidosis MDI
z = 1.620
Prob > |z| = 0.1052
https://doi.org/10.1371/journal.pone.0217655.t006
Fig 4. Pooled HbA1c results (MD) at baseline.
https://doi.org/10.1371/journal.pone.0217655.g004
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and the heterogeneity in study design and methodology, the appropriateness of a meta-analysis
has to be critically questioned and the results of this review should be seen in the context of the
stated limitations.
Huge heterogeneity could be found regarding case ascertainment (Table 9). The quality of
studies was assessed using the EPHPP quality assessment tool for quantitative studies (S1
Table). The tool generates a total quality score between one (strong) and three (weak) based
on six sub-scores, assessing components of internal and external validity.[22] All but two of
the studies were awarded three points.[8, 35] Most papers were rated weak because of a lack in
blinding (due to the nature of the exposure) and not mentioning validity and reliability of the
applied assessment tools for QoL. In addition, all of the included CSS were awarded weak com-
ponent ratings for study design. Overall, the evidence base is rated as weak. However, the
Fig 5. Pooled HbA1c results (MD) at follow-up.
https://doi.org/10.1371/journal.pone.0217655.g005
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applied tool might not be ideal for rating the quality of studies on insulin treatment regimens
since some of the assessed components seem to be inappropriate (e.g. blinding). Also, the tool
does not address and rate patient reported outcome measures like QoL or treatment satisfac-
tion specifically.
Nowadays, the biggest challenge in paediatric diabetes therapy is reaching optimal glycae-
mic control while maintaining the highest possible QoL for children and their parents or care-
givers.[8] Different aspects seem to be of importance for reaching this goal. Positive
Table 7. Limitations of the included literature.
Limitation Potential issue
Differences in study design - No exclusion criteria were defined regarding study design
-! Inclusion of six RCT[8, 15, 33, 39, 42, 43] (strongest design when assessing
primary data[44]) as well as several other study types (CSS, CT, prospective
observational)
- The latter do not include randomisation and thus, cannot rule out whether
differences in outcome are caused by the exposure or influenced by differences
in other observed and unobserved characteristics between groups
-! Possible introduction of systematic error
Differences in sample size - Eight of the studies[31–33, 37, 39, 41–43] included less than 100 patients with
two studies reporting for only fifteen[41] and sixteen[43] patients respectively
-!With small sample sizes, observed results are more likely to be caused by
chance and might not be representative of the population
Differences in study location - Only studies from the USA, Europe and Israel were included, recruiting
patients from one to eighteen different study sites within the respective countries
-! Potential source of selection bias
Differences in primary data
source
- One study used a national registry as data source[36]
- Three studies[31, 34, 40] recruited their participants from diabetes summer
camps
-! Potential source of selection bias
Differences in age - Age groups differed between studies (Table 3)
-! Parents answered questionnaires as proxies for younger children (Table 9)
which might mitigate the comparability between studies
Differences in adjustment for
confounders
- No consistent reporting (Table 3)
-! Six studies did not state any adjustment[31–33, 35, 41, 43] and thus,
existence of residual, unaddressed and unidentified confounding throughout
studies cannot be ruled out
https://doi.org/10.1371/journal.pone.0217655.t007
Table 8. Limitations of the review.
Limitation of review Potential issue
Number of databases - Only three databases were used for literature search
-! Potential selection bias which could mitigate representativeness of the results
Accessibility of
studies
- Full-texts could not be accessed for twelve possibly relevant studies
- Search was limited to titles and abstracts in English only
-! Potential selection bias
Differences in
reporting
- Two studies reported medians and IQR for HbA1c only,[15, 38] five studies did not report
overall QoL scores[31, 34, 38, 42, 43] and four studies did neither report CI nor standard
error[33, 35–37]
-! Only a very small number of studies was included in the analyses which mitigates the
generalisability of the results and increases the probability of them occurring by chance
alone
Publication bias - Studies reporting significant or interesting results are more likely to be published
-! The findings of this review are likely to be affected by publication bias.
Registration - This paper has not been registered through PROSPERO prior to publication
-! The risk of other reviews addressing the same question being published simultaneously
cannot be ruled out
https://doi.org/10.1371/journal.pone.0217655.t008
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relationships as well as good glycaemic control and sufficient self-management have been
shown to substantially decrease the burden DM inflicts on the affected individuals.[18] In this
respect, recent technological developments in insulin application methods like CSII systems
have improved insulin therapy through providing more flexibility.[45] Through CSII paediat-
ric patients can carry out precise insulin dose adjustments and have greater independence and
more responsibility.[46] These attributes are considered main benefits of CSII.[47] However,
recent reviews solely showed that QoL in T1DM children and adolescents using CSII is slightly
higher or similar to QoL in MDI patients.[18, 19] In contrast, Blair et al. stated in 2018 that
CSII is neither cost-effective nor clinically superior to MDI.[15] Partly aligned with this, this
analysis could in fact show significant differences in QoL at both, baseline and follow-up but
no significant change over time could be observed. Having said that, glycaemic control proved
to be considerably better in CSII patients but no change over time could be seen. In addition
to QoL and glycaemic control, acute complications associated with CSII need to be addressed
since these are major concerns for patients when transitioning to CSII.[18] Most studies with
short follow-up periods did not show any difference in adverse events between treatment
groups whereas studies with follow-up times of more than one year showed decreased adverse
event rates for CSII patients.[18] This review concurs previous findings. However, due to the
follow-up times of the included evidence, no long-term effects of CSII on morbidity and mor-
tality in T1DM patients could be assessed. This proves an important limitation since chronic
complications of T1DM can impose an enormous additional burden on patients’ lifestyle with
detrimental effects to their QoL. Due to several methodological limitations and vast heteroge-
neity in the included evidence, recommendations based on this review should be considered
with due care. We could not show considerable superiority of CSII over MDI regarding QoL
in paediatric patients. Thus, it cannot be recommended to replace MDI as first-choice treat-
ment in T1DM youth. However, since outcomes regarding QoL and glycaemic control could
be shown to be similar to MDI and decreased mortality because of long-term complications in
CSII patients has been described in previous studies[48], public health professionals should
reconsider including CSII as an additional first-line treatment in T1DM equal to MDI.
Table 9. Exposure and outcome ascertainment for included studies.
Differences in case ascertainment
Exposure Diabetes duration prior
to study
- Minimum duration of diabetes before study entry ranged between six
months and two years for ten studies, was not defined for four studies[31, 33,
34, 36] and Blair et al. only included newly diagnosed children
Follow-up time - Follow-up times ranged from 3.5 to 12 months in length with six studies
reporting no times due to their cross-sectional design[31, 32, 34, 36, 38, 40]
Insulin delivery - The same well-established MDI and CSII definitions were applied
throughout studies
- Insulin and delivery system types varied greatly between studies
Outcome QoL - The fifteen studies used eight different QoL assessment tools (Table 4) with
one study not specifying the used tool[37]
- Parents answered questionnaires for children in younger age groups[8, 15,
33, 35, 39, 41]
- Four studies did not report overall QoL scores[31, 34, 42, 43]
- Baseline data on QoL could only be included for three studies[8, 33, 39]
Adverse events - Only nine out of fifteen studies reported results on adverse events
- Results were presented in events per person time[38, 39, 41–43] as well as
crude number of events per treatment group[15, 33, 35, 37]
HbA1c - Fourteen studies reported HbA1c in % whereas Blair used mmol/mol
- Different HbA1c analysers were used throughout studies with some CSS
using the latest HbA1c values reported by caregivers or retrieved from patient
records
https://doi.org/10.1371/journal.pone.0217655.t009
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Conclusion
This paper set out to analyse whether CSII regimens are superior to MDI therapy in T1DM
youth regarding HRQOL. Additionally, it assessed glycaemic control and adverse events as
secondary outcomes and discussed potential future public health implications and justifica-
tions for using CSII as a first-line therapy in children and adolescents. Despite the stated limi-
tations and the fact that no considerable difference in QoL between treatment groups could be
shown over time, CSII proved to provide similar or slightly better outcomes in all analysed
fields. This is consistent with previous research. However, to make credible and reliable rec-
ommendations, bigger, better-powered and better-designed studies are needed to investigate
the impact of CSII in children. Poor methodology, small samples and short follow-up times
constrain the ability to assess the association between QoL and CSII to the full extent.[17]
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